Friday, November, 16, 2018 05:39:52

Akcea, Ionis attain FDA approval for hATTR treatment drug, Tegsedi™

Leading pharmaceutical conglomerate, Akcea Therapeutics and parent Ionis Pharmaceuticals Inc. have recently received approval for their hereditary transthyretin amyloidosis (hATTR) treatment drug, Tegsedi™ by the U.S. Food and Drug Administration (FDA). hATTR being a rare disease causes buildup of amyloid in the peripheral nervous system and …

Novartis announces FDA, EMA approval of SPMS drug, Siponimod

Swiss pharmaceutical conglomerate, Novartis International AG, has recently announced the acceptance of its secondary progressive multiple sclerosis (SPMS) treatment drug, Siponimod, by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The effects of multiple sclerosis (MS) can significantly impact lives, …

Pharma giant Merck opens M Lab™ Collaboration Center in Brazil

American pharmaceutical conglomerate, Merck & Co. has recently inaugurated a state-of-the-art M Lab™ Collaboration Center in São Paulo, Brazil, so as to serve customers in the Latin America region. Sources suggests that the center will effectively provide life science customers with a shared, exploratory environment, …